Form 4 for ETON Eton Pharmaceuticals, Inc.
Accepted 2026-05-29 16:16:53 ET · period of report 2026-05-28 · accession 0001437749-26-018879 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-05-29 16:16 | 2026-05-28 | ETON | BRYNJELSEN SEAN | Pres, CEO, Dir | S - Sale | $31.88 | -120.0K | 833.7K | -13% | -$3.83M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-28 | S | D | 119,852 | $31.88 | 833,842 | D | — | — | (F1) The shares were sold in multiple trades at prices ranging from $31.59 to $32.55. The price above reflects the weighted average sales price. (F2) The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2026-05-28 | S | D | 148 | $32.67 | 833,694 | D | — | — |